Literature DB >> 27225279

Mobitz type I and II atrioventricular blocks during fingolimod therapy.

Francesco Saccà1, Giorgia Puorro2, Angela Marsili2, Chiara Pane2, Cinzia Valeria Russo2, Roberta Lanzillo2, Anna de Rosa2, Antonio Cittadini3, Giuseppe De Angelis4, Vincenzo Brescia Morra2.   

Abstract

We investigated patients who showed a second-degree atrioventricular block (S-AVB) after the first fingolimod administration. We observed six patients with S-AVB, three Mobitz type I, and three type II. Monitoring continued on the second day for all patients. Three patients showed persistence of the S-AVB, with resolution on the second or third day. One patient had a persistent S-AVB up to the fourth day when fingolimod was discontinued. We conclude that Mobitz type II S-AVB is possible during fingolimod therapy. Patients with S-AVB could be monitored until resolution of the S-AVBs, as these may persist several days after the first fingolimod administration.

Entities:  

Keywords:  Atrioventricular block; Cardiac safety; Fingolimod; Mobitz type II; Multiple sclerosis; Relapsing; Tolerability; Treatment

Mesh:

Substances:

Year:  2016        PMID: 27225279     DOI: 10.1007/s10072-016-2621-y

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  6 in total

1.  FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects.

Authors:  Robert Schmouder; Denise Serra; Yibin Wang; John M Kovarik; John DiMarco; Thomas L Hunt; Marie-Claude Bastien
Journal:  J Clin Pharmacol       Date:  2006-08       Impact factor: 3.126

2.  Woldemar Mobitz and His 1924 classification of second-degree atrioventricular block.

Authors:  Mark E Silverman; Charles B Upshaw; Helmut W Lange
Journal:  Circulation       Date:  2004-08-31       Impact factor: 29.690

3.  A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

Authors:  Ludwig Kappos; Ernst-Wilhelm Radue; Paul O'Connor; Chris Polman; Reinhard Hohlfeld; Peter Calabresi; Krzysztof Selmaj; Catherine Agoropoulou; Malgorzata Leyk; Lixin Zhang-Auberson; Pascale Burtin
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

Review 4.  Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.

Authors:  Jerold Chun; Hans-Peter Hartung
Journal:  Clin Neuropharmacol       Date:  2010 Mar-Apr       Impact factor: 1.592

5.  Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study.

Authors:  Ralf Gold; Giancarlo Comi; Jacqueline Palace; Arno Siever; Rebecca Gottschalk; Mahendra Bijarnia; Philipp von Rosenstiel; Davorka Tomic; Ludwig Kappos
Journal:  J Neurol       Date:  2013-11-13       Impact factor: 4.849

6.  Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial.

Authors:  Alice Laroni; Davide Brogi; Vincenzo Brescia Morra; Leonello Guidi; Carlo Pozzilli; Giancarlo Comi; Alessandra Lugaresi; Renato Turrini; Debora Raimondi; Antonio Uccelli; Giovanni Luigi Mancardi
Journal:  BMC Neurol       Date:  2014-04-01       Impact factor: 2.474

  6 in total
  2 in total

1.  Asymptomatic bradycardia after first fingolimod dose in a pediatric patient with multiple sclerosis - a case report.

Authors:  Martina Petruzzo; Roberta Lanzillo
Journal:  Neurol Sci       Date:  2021-02-26       Impact factor: 3.307

2.  Gender differences in safety issues during Fingolimod therapy: Evidence from a real-life Relapsing Multiple Sclerosis cohort.

Authors:  Alessia Manni; Vita Direnzo; Antonio Iaffaldano; Valentina Di Lecce; Carla Tortorella; Stefano Zoccolella; Pietro Iaffaldano; Maria Trojano; Damiano Paolicelli
Journal:  Brain Behav       Date:  2017-08-29       Impact factor: 2.708

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.